Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Non-Hodgkin Lymphoma. Found 10 abstracts

Talekar MK, Allen JE, Dicker DT, El-Deiry WS. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells. Cell cycle (Georgetown, Tex). 2015 Aug;14(15):2422-8.   PMCID: PMC4614396
Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, Rosen ST, Gordon LI. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. Br J Haematol. 2014 Aug;166(4):514-20.
Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F, National Comprehensive Cancer N. Non-Hodgkin's lymphomas. J Natl Compr Canc Netw. 2008 Apr;6(4):356-421.
Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol. 2006 Jul;24(19):3107-12.
Borghaei H, Schilder RJ. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). Seminars in Nuclear Medicine. 2004 Jan;34(1 Suppl 1):4-9.
Borghaei H, Wallace SG, Schilder RJ. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clinical Lymphoma. 2004 Oct;5 Suppl 1:S16-21.
Laport GG, Levine BL, Stadtmauer EA, Schuster SJ, Luger SM, Grupp S, Bunin N, Strobl FJ, Cotte J, Zheng Z, Gregson B, Rivers P, Vonderheide RH, Liebowitz DN, Porter DL, June CH. Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood. 2003 Sep 15;102(6):2004-13.
Roberts JD, Smith MR, Feldman EJ, Cragg L, Grant S. Phase I study of bryostatin-1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Clin Lymphoma. 2002 Dec;3(3):184-8.
Young NA, Al-Saleem TI, Al-Saleem Z, Ehya H, Smith MR. The value of transformed lymphocyte count in subclassification of non-Hodgkin's lymphoma by fine-needle aspiration. American journal of clinical pathology. 1997 Aug;108(2):143-51.
Meyuhas O, Thompson EA, Perry RP. Glucocorticoids selectively inhibit translation of ribosomal protein mRNAs in P1798 lymphosarcoma cells. Mol Cell Biol. 1987 Aug;7(8):2691-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma therapeutic use drug therapy Non-US Gov't Support Human Male Aged Middle Aged Treatment Outcome Antineoplastic Agents Female Adult Antineoplastic Combined Chemotherapy Protocols rt [Radiotherapy] Cytarabine adverse effects Yttrium Radioisotopes Immunotherapy pharmacology classification drug effects immunology therapy tu [Therapeutic Use] Prognosis methods metabolism diagnosis ae [Adverse Effects] Monoclonal Antibodies cancer Radioimmunotherapy Tumor Biomarkers Safety Nhl Cellular Immunity TNF-Related Apoptosis-Inducing Ligand Tumor Cell Line Follow-Up Studies Messenger RNA Prospective Studies Ribosomal DNA genetics Immunoglobulin Idiotypes analogs & derivatives Vidarabine Lymphocyte Activation 0 (ibritumomab tiuxetan) analysis Combined Modality Therapy Adoptive Transfer US Gov't Support-PHS Heterocyclic Compounds with 4 or More Rings Antibody Formation Cell Survival CD20) 0 (Antigens prognosis Retrospective Studies follicular lymphoma tumor necrosis family TNF Needle Biopsy Tic10 Adolescent US Gov't Support-Non-PHS death receptor 5 DR5 Genetic Translation Dexamethasone Rituximab T-Lymphocytes Stem Cell Transplantation Apoptosis pd [Pharmacology] Hemocyanin Cancer Vaccines mt [Methods] Pyrazines Monoclonal) 0 (Antibodies Tumor Necrosis Factor Receptors Monoclonal Antibodies-Murine-Derived Lymphocytosis Flow Cytometry CD34 Antigens treatment Genetic Transcription im [Immunology] Carmustine Lymphocyte Count Polyribosomes Trail Risk Factors Survival Analysis blood Lactones chemistry 80 and over Aged Lymphocytes TNF-related apoptosis-inducing ligand TRAIL Remission Induction 0 (Yttrium Radioisotopes) Onc201 Ribosomal Proteins Lymphocytic Leukemia-Chronic Hematopoietic Stem Cells Local Neoplasm Recurrence lymphoma Second Primary Neoplasms Etoposide Cell Line Recurrence pathology Neoplasm Staging Bortezomib Immunophenotyping transplantation mortality Boronic Acids administration & dosage Mice Kinetics non-Hodgkin's lymphoma NHL Cyclophosphamide Child Hematopoietic Stem Cell Transplantation CD20 Antigens
Last updated on Sunday, July 05, 2020